Physicians' Academy for Cardiovascular Education

Improvement quality of life with sacubitril/valsartan in heart failure

Health-Related Quality of Life Outcomes in PARADIGM-HF

Literature - Lewis EF, Claggett BL, McMurray JJV, et al. - Circulation: Heart Failure. 2017; Epub ahead of print

Main results

Conclusion

In patients with HFrEF, sacubitril/valsartan was superior to enalapril in improving disease-specific HRQL in PARADIGM-HF, despite the relatively higher baseline KCCQ scores that were established after the run-in period that may have mitigated the magnitude of improvement. This difference between treatments was already noted after 4 months and persisted through month 36 and was particularly true for patients hospitalized for HF.

References

Show references

Find this article online at Circulation

Share this page with your colleagues and friends: